ank-101
Recombinant proteinexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2023 (NCT06171750)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-12 subunit betaSupplementation
IL12B supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07100925 | Phase 1 | Dec 15, 2025 | Ankyra Therapeutics, Inc, Harvard University |
| NCT07027514 | Phase 1 | Oct 22, 2025 | Ankyra Therapeutics, Inc |
| NCT06171750 | Phase 1 | Dec 31, 2023 | Ankyra Therapeutics, Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ankyra Therapeutics, Inc | For profit | 3 | 3 | 1 | 2023 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1